The DevelopAKUre programme is a huge European network that has 12 members, called the consortium. It is made up of hospitals, pharmaceutical companies, universities, biotech companies and national AKU patient groups that are based all over Europe. Each member of the consortium has a specific role that promotes one another and allows DevelopAKUre to pool together resources in order to reach their shared end goal – an effective treatment for alkaptonuria.
DevelopAKUre is a series of major international clinical trials, run by a consortium of 12 European partners. It aims to study a potential new drug, called nitisinone, and assess its potential effectiveness in treating the rare disease, alkaptonuria (AKU).
DevelopAKUre is co-funded by a grant from the European Commission. This website is run by a UK patient group, the AKU Society. Learn more about AKU on the AKU Society's What is AKU page.
In today’s blog Chief investigator Prof. Ranganath reinforces the need for SONIA 2 pat.. ...more